The annual meeting of the Cure Alzheimer’s Fund Research Consortium was held in February in San Diego. Eighteen members of the consortium attended, as well as key staff and board members of Cure Alzheimer’s Fund. The two-day session provided the researchers with an opportunity to share their work, including insights and findings.
Beth Stevens, Ph.D., of Boston Children’s Hospital reviewed how the complement pathway, which “prunes” synapses in normally developing brains, also may be involved in early synapse loss in the Alzheimer’s brain. In addition, Tony Wyss-Coray, Ph.D., of Stanford University discussed the impact of young blood plasma on memory, while Karen Duff, Ph.D., of Columbia University shared her findings on the damage to brains from excess tau protein. Finally, David Holtzman, M.D., of Washington University in St. Louis, provided an update regarding the influence of the APOE gene on Alzheimer’s.
“One of our founding principles is to have open collaboration among our researchers,” said Tim Armour, President and CEO of Cure Alzheimer’s Fund. “This meeting provides an in-person forum where the scientists can share publicly available and confidential information fostering open discussion about the progress being made in Alzheimer’s research, as well as the challenges that may be impeding that progress. The meeting is dynamic and extremely valuable for advancing the understanding of the science.”
This meeting provides an in-person forum where the scientists can share publicly available and confidential information fostering open discussion about the progress being made in Alzheimer’s research.